Market Size of Brazil Drug Delivery Devices Industry
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2021 - 2022 |
CAGR | 4.50 % |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Brazil Drug Delivery Devices Market Analysis
The Brazil drug delivery devices market is expected to register a CAGR of 4.5% over the forecast period.
COVID-19 had a significant impact on the Brazil drug delivery devices market in early 2020 owing to the factors such as country-wide lockdowns leading to less export and import of drug delivery devices. For instance, according to the article published in May 2021 in PubMed, Cruz Foundation (Fiocruz) revealed that the prevalence of acute respiratory distress syndrome (ARDS) in Brazil significantly increased during the pandemic, which was likely explained by several COVID-19 cases being diagnosed as acute respiratory distress syndrome (ARDS). Hence, most people utilize nebulizers and inhalers to alleviate breathing difficulty. As a result, the demand for drug delivery devices increased in Brazil. Furthermore, drug delivery devices export and import got delayed, making the situation challenging in the initial pandemic phases. However, the market is currently showing stable growth and is expected to follow the same over the next 3-4 years. Factors such as an increase in the number of chronic diseases and the rise in research and development activities are anticipated to boost the market growth in the coming years.
The high prevalence of chronic diseases is likely to increase the demand for drug-delivery devices, which is anticipated to boost the market growth. For instance, according to the IDF Diabetes Atlas 2021, 15,733,600 people were affected with diabetes in Brazil in 2021. The rising incidence of diabetes is likely to demand insulin drug delivery devices, expected to drive the drug delivery devices market in Brazil over the forecast period. Furthermore, the presence of competitors, mergers acquisition, and collaboration in the studied region is likely to increase the market growth as these improve the chances of product availability and competition. For instance, in February 2022, Eurofarma, a multinational pharmaceutical business with 100% Brazilian capital, introduced the generic medicine dexamethasone + thiamine hydrochloride + pyridoxine hydrochloride + cyanocobalamin, indicated for the treatment of inflammatory neuropathies. The medicine is available in pharmacies throughout Brazil as an injectable solution in packages of six ampoules. Hence, product launches relating to drug delivery devices like injectables will likely boost market growth over the forecast period.
Hence, due to the rise in the prevalence of chronic diseases and the high demand for drug delivery devices, Brazil's drug delivery devices market is expected to witness growth over the forecast period. However, the risk associated with needlestick injuries may restrain the market growth over the forecast period.
Brazil Drug Delivery Devices Industry Segmentation
As per the scope of the report, drug delivery devices or systems are the tools used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances into the body. The Brazil Drug Delivery Devices Market is Segmented by Route of Administration (Injectable, Topical, Ocular, and Others), Application (Cancer, Cardiovascular, Diabetes, Infectious Diseases, and Other Applications), End User (Hospitals, Ambulatory Surgical Centers, and Other End Users). The report offers the value (in USD million) for the above segments.
By Route of Administration | |
Injectable | |
Topical | |
Ocular | |
Other Route of Administration |
By Application | |
Cancer | |
Cardiovascular | |
Diabetes | |
Infectious diseases | |
Other Applications |
By End User | |
Hospitals | |
Ambulatory Surgical Centers | |
Other End Users |
Brazil Drug Delivery Devices Market Size Summary
The Brazil drug delivery devices market is poised for steady growth, driven by an increasing prevalence of chronic diseases and advancements in research and development. The market experienced initial disruptions due to the COVID-19 pandemic, which affected the import and export of devices but subsequently saw a rise in demand for products like nebulizers and inhalers. The growing incidence of conditions such as diabetes is expected to boost the demand for insulin delivery devices, while the ocular segment is anticipated to expand due to the rising cases of eye diseases and related research. The market's growth is further supported by strategic activities such as mergers, acquisitions, and product launches, which enhance the availability and competitiveness of drug delivery devices in the region.
Infectious diseases also contribute to the market's expansion, with an increase in cases prompting a higher demand for vaccination-related devices like syringes and prefilled syringes. The market is characterized by a fragmented landscape with both global and regional players, including major companies like Sanofi, GSK plc, and Pfizer Inc. Ongoing research and clinical trials in infectious disease prevention and treatment are expected to further drive market growth. Despite the positive outlook, challenges such as the risk of needlestick injuries may pose constraints. Overall, the Brazil drug delivery devices market is set to experience growth, supported by technological advancements, increasing healthcare needs, and strategic industry developments.
Brazil Drug Delivery Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Chronic Diseases
-
1.2.2 Increased Funding and Research Activity in Drug Development
-
-
1.3 Market Restraints
-
1.3.1 Risk Associated With Needlestick Injuries
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Route of Administration
-
2.1.1 Injectable
-
2.1.2 Topical
-
2.1.3 Ocular
-
2.1.4 Other Route of Administration
-
-
2.2 By Application
-
2.2.1 Cancer
-
2.2.2 Cardiovascular
-
2.2.3 Diabetes
-
2.2.4 Infectious diseases
-
2.2.5 Other Applications
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Ambulatory Surgical Centers
-
2.3.3 Other End Users
-
-
Brazil Drug Delivery Devices Market Size FAQs
What is the current Brazil Drug Delivery Devices Market size?
The Brazil Drug Delivery Devices Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Brazil Drug Delivery Devices Market?
Sanofi, GSK plc, Pfizer Inc., Novartis AG and Eurofarma are the major companies operating in the Brazil Drug Delivery Devices Market.